2026-01-04 - Analysis Report
Here's a breakdown of the TG Therapeutics (TGTX) analysis based on the provided data, presented in a clear and organized manner:

**1. Return Rate Comparison:**

*   **TGTX Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 69.10%
*   **S&P 500 (VOO) Cumulative Return:** 91.00%
*   **Divergence:** -18.70 (Relative Divergence: 16.3)

**Analysis:** TGTX has underperformed the S&P 500 significantly over the measured period. The divergence of -18.70 indicates that TGTX's cumulative return is 18.7 percentage points lower than the S&P 500's. The relative divergence of 16.3 suggests TGTX is currently performing near the low end of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha    | Beta | Cap(B) |
|------------|---------|-------|----------|------|--------|
| 2016-2018  | -53.0%  | 71.9% | -56.0%   | 1.8  | 0.7    |
| 2017-2019  | 71.0%   | 71.9% | 54.0%    | 1.8  | 1.8    |
| 2018-2020  | 332.0%  | 71.9% | 311.0%   | 1.6  | 8.3    |
| 2019-2021  | 130.0%  | 66.3% | 86.0%    | 1.6  | 3.0    |
| 2020-2022  | -86.0%  | 90.0% | -84.0%   | 1.9  | 1.9    |
| 2021-2023  | -315.0% | 89.7% | -316.0%  | 2.4  | 2.7    |
| 2022-2024  | 57.0%   | 76.8% | 38.0%    | 2.3  | 4.8    |
| 2023-2025  | 67.0%   | 76.8% | 4.0%     | 1.1  | 4.7    |

**Analysis:**

*   **Volatility:** TGTX exhibits high volatility, as evidenced by the significant fluctuations in CAGR and substantial Maximum Drawdown (MDD) values. This suggests a risky investment.
*   **Alpha:** Alpha, representing excess return compared to the market, varies significantly. While some periods show strong positive alpha (outperformance), others display substantial negative alpha (underperformance).
*   **Beta:** Beta values consistently above 1 indicate that TGTX's price is more sensitive to market movements than the overall market. Beta has generally been decreasing.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 29.28
*   **Previous Close:** 29.81
*   **Change:** -1.78%
*   **5-day SMA:** 30.028
*   **20-day SMA:** 30.7325
*   **60-day SMA:** 32.2716

**Analysis:** TGTX is currently trading below its 5-day, 20-day, and 60-day simple moving averages (SMAs). This suggests a short-term downtrend. The negative change in price further supports this observation.

**3. Market Indicators:**

*   **MRI:** 0.8 (Medium Investment)
*   **RSI:** 29.70 (Oversold)
*   **PPO:** -0.3366
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (31 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.8 (Negative - Short-term decline)
*   **Expected Return:** -71.7%

**Analysis:**

*   **MRI:** The Market Risk Indicator (MRI) of 0.8 suggests a medium level of investment risk based on this single metric.
*   **RSI:** An RSI of 29.70 indicates that the stock is currently oversold, potentially signaling a possible rebound.
*   **PPO:** The negative PPO suggests a downtrend in price momentum.
*   **Hybrid Signal:** The hybrid signal is aggressive by suggesting a large buy (31 shares with 100% cash)
*   **Divergence Change:** The recent negative change in relative divergence suggests a short-term decline.
*   **Expected Return:** The extremely low expected return (-71.7%) is concerning and suggests significant challenges for the stock.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **Mixed Sentiment:** The news headlines present a mixed picture:
    *   **Positive Notes:** Some articles suggest underlying financial strength and opportunities.
    *   **Negative Notes:** Other articles point to weaknesses, earnings caveats, and potential market volatility.
    *   **Overall:** The news flow seems cautiously optimistic but acknowledges risks and uncertainties.

**4-2. Analyst Opinions:**

*   **Consensus:**  No consensus rating available.
*   **Target Price:** Average target price is $44.29, with a wide range ($13.00 - $60.00), reflecting uncertainty among analysts.
*   **Recent Rating Changes:** No specific rating changes provided.

**Analysis:** The lack of a strong consensus and the wide target price range indicate that analysts have varying opinions on the future performance of TGTX.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-11-05 | 2.69  | 0.16 B$  |
| 2025-08-08 | 0.19  | 0.14 B$  |
| 2025-05-09 | 0.03  | 0.12 B$  |
| 2024-11-07 | 0.03  | 0.08 B$  |
| 2025-11-05 | 0.03  | 0.08 B$  |

**Analysis:** The EPS is variable with a large spike on 2025-11-05 with the revenue is increasing. The significant jump in EPS on 2025-11-05 warrants investigation.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.16B  | 82.63%        |
| 2025-06-30 | $0.14B  | 86.58%        |
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-09-30 | $0.61B   | 64.37%    |
| 2025-06-30 | $0.28B   | 10.20%    |
| 2025-03-31 | $0.24B   | 2.13%     |
| 2024-12-31 | $0.22B   | 10.49%    |
| 2024-09-30 | $0.19B   | 2.02%     |

**Analysis:** Revenue is on a general upward trend, and profit margins are very high, which is a positive sign. Equity has increased significantly, particularly in the most recent quarter, and ROE is also very high for that quarter, indicating efficient use of equity to generate profits during that period.

**7. Comprehensive Analysis (Summary):**

TG Therapeutics (TGTX) presents a mixed investment picture:

*   **Underperformance:** It has significantly underperformed the S&P 500.
*   **Volatility:** High volatility makes it a risky investment.
*   **Technical Indicators:** Technical indicators suggest a short-term downtrend. The RSI indicates that the stock is oversold, presenting a possible rebound.
*   **Analyst Uncertainty:** Analyst opinions are divided, as reflected in the lack of consensus and wide target price range.
*   **Financials:** Revenue is increasing and high profit margins, and significant changes in equity and ROE are positive.
*   **News Sentiment:** The news flow reflects both opportunities and risks.
*   **Earnings:** EPS is volatile with a large spike in the most recent quarter
*   **Overall Assessment:** Based on this data, TGTX appears to be a speculative investment with a high degree of risk. The recent downtrend, analyst uncertainty, and negative expected return are concerning. However, the increasing revenue and high profit margins offer some potential upside if the company can maintain its profitability and address the concerns reflected in the news and analyst opinions. More detailed investigation of the spike in EPS, and the reasons for the large increase in equity and ROE would be warranted.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.